New York · Pre-Seed–Series B · 17 people tracked
Also known as Medical Excellence Capital Partners ll · MEDICAL EXCELLENCE CAPITAL, LLC
Investment thesis
MEC is a purpose-built venture firm investing in precision health and life sciences innovation. It backs company creation, seed, Series A, and Series B opportunities where technology and novel approaches — often leveraging artificial intelligence — are transformative for patient care and address large, unmet medical needs. The firm believes the coming decade will bring a golden age of life sciences innovation driven by AI, and it deploys 'precision capital' supported by a proprietary national medical network platform to nurture companies solving the biggest and most complex medical problems.
Source: firm website, verified Aug 25, 2026.
Team · 17 people
from the firm's website & public directories
What they invest in
from 14 of 19 portfolio companiesBiotech ×14Medical Devices ×7Deep Tech ×6Healthtech ×5Digital Health ×3AI & Machine Learning ×2Hardware ×1
HQs:United States×11
Investments · 19 tracked
founders shown can be your intro pathBy year:2022 · 22021 · 13 dated
ProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS).
BiotechDeep TechMedical DevicesNissequogue, US
Valerie Estess(Director)
BoardJohn Prufeta(Director)inJoni Mancini(Executive Officer)inBrent R. Stockwell(Chair of the Department of Biological Science, Professor at Columbia University)Hynek Wichterle(Jerry and Emily Spiegel Professor at Columbia University)
Board seatEric Heil· per SEC Form D
Ladder Bio (formerly ThirdLaw Molecular) develops Spiroligomer molecules, a class of synthetic, modular fused-ring compounds designed for highly selective binding to target proteins, along with computational design tools for targeted drug discovery.
BiotechDeep TechMedical DevicesBlue Bell, US
Christian Schafmeister(Founder)Eric Heil(Chief Executive Officer)in
Co-investorsSmartGateVC
Pleno develops a genomic testing instrument platform designed to make multiomics testing faster, lower-cost, and higher-plex than existing methods like NGS, PCR, and microarrays.
BiotechHardwareHealthtech
Co-investorsForesite CapitalDeerfield Management Company
Ladder Bio (formerly ThirdLaw Molecular) develops Spiroligomer molecules, a class of synthetic, modular fused-ring compounds designed for highly selective binding to target proteins.
BiotechDeep TechMedical DevicesBlue Bell, US
Christian Schafmeister(Founder)Eric Heil(Chief Executive Officer)in
Co-investorsSmartGateVC
BiotechNew York, US
Andrea Spezzi(Executive Officer, Director)
BoardJohn Prufeta(Director)in
Board seatEric Heil· per SEC Form D · $5M raise · filed Sep 2022
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical Devices
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)
Co-investorsARCH Venture PartnersLifeforce CapitalOrbiMedDomain AssociatesEDB InvestmentsSection 32+3 more
Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process.
BiotechWaltham, US
THERESA CAMERON(Director)MARTIN FREED(Director)STEPHANIE TOZZO(Executive Officer)PHIL GRAHAM(Executive Officer)MILIND DESHPANDE(Director)DAVID NEAFUS(Executive Officer)
Co-investorsAstellas Venture Management LLCRA CapitalSanofi VenturesOpenSky Ventures
Company developing oral small-molecule CLIC1 inhibitors to treat obesity and metabolic diseases through hunger-pathway modulation.
ClicBio develops oral small-molecule CLIC1 inhibitors to treat metabolic diseases by modulating appetite through hypothalamic neuron regulation.
BiotechDeep TechHealthtech
John Dobak(CEO and Co-Founder)Jay Hagan(Board Member and Co-Founder)Bruce Steel(Board Member and Co-Founder)Olivia Osborn(Co-Founder/Advisor)
GCTx develops an induced pluripotent stem cell (iPSC) programming platform called TFome™ that uses synthetic biology, gene editing, and machine learning to improve cell therapy development and scaling.
AI & Machine LearningBiotechMedical DevicesCambridge, US
George Church(Co-Founder & Scientific Advisor)Parastoo Khoshakhlagh(Chief Executive Officer & Co-Founder)Alex Ng(Chief Innovation Officer & Co-Founder)
Co-investorsAndreessen HorowitzGlobal BrainHumboldt
Precision immunotherapy company using single-cell genomics and machine learning to develop novel cancer treatments, with lead programs in clinical development.
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Amanda Wagner(Executive Officer)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
BoardLaura Brass(Director)inKai Wucherpfennig(Director)
Co-investorsDC Investment PartnersLongwood FundNovartis Venture FundOno Venture Investment, Inc.Solasta VenturesAgent Capital+2 more
Biotech company developing Spiroligomer™ molecules as a new class of targeted therapeutic medicines for diagnostic and therapeutic applications.
Spinout from Children's Hospital of Philadelphia using AI and machine learning to develop therapies for genetic diseases in children.
Nobias Therapeutics is a clinical-stage drug developer creating small-molecule therapeutics for genetically-defined rare diseases, initially focused on pediatric indications with potential expansion into adult and non-rare conditions.
AI & Machine LearningBiotechHealthtech
Hakon Hakonarson(Co-Founder and Chief Scientific Advisor)Brian Halak(Co-Founder)Patrick Dougherty(Chief Executive Officer)Ryan McMillian(Consulting Chief Financial Officer)
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Co-investorsVida VenturesLeaps by BayerFoothill VenturesIllumina VenturesVivo CapitalARCH Venture Partners+1 more
San Diego biotech founded in 2019 developing oral anti-inflammatory small molecules targeting RNA binding proteins.
Co-investorsARCH Venture PartnersLightstone Ventures
Truvian builds an on-site blood diagnostics platform that combines clinical chemistry, immunoassay, and hematology testing in a single compact instrument.
BiotechDigital HealthMedical DevicesSan Diego, US
Dena Marrinucci(Co-Founder & Chief Operating Officer)inMichael J. Mina(Chief Medical and Strategy Officer)
Co-investorsDns CapitalGreatPoint VenturesWittington VenturesDomain AssociatesOS Fund
TwoStep Therapeutics is a Stanford spinout developing targeted cancer therapies, including peptide-based drug conjugates and radioligand programs built on a tumor-targeting peptide platform.
BiotechHealthtechSan Carlos, US
Caitlyn Miller(CEO & Co-Founder)Jennifer Cochran(Co-Founder)Carolyn Bertozzi(Co-Founder)Ronald Levy(Co-Founder)
BoardOmri Amirav-Drory(Director)inJohn Prufeta(Director)in
Co-investors2048 VenturesFifty YearsNFX
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Portfolio news
latest coverage across their companies
SonoThera · statnews.com · Jul 17, 2026
GC Therapeutics · nasdaqprivatemarket.com · Apr 3, 2026
Aspen Neuroscience · longevity.technology · Nov 24, 2025
Frequently asked questions
- How many investments has Medical Excellence Capital made?
- Medical Excellence Capital has 16 tracked investments.
- What stage does Medical Excellence Capital invest at?
- Medical Excellence Capital invests at the Pre-Seed, Seed, Series A, Series B stages.
- What sectors does Medical Excellence Capital focus on?
- Medical Excellence Capital focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Medical Excellence Capital located?
- Medical Excellence Capital is headquartered in New York, US.
- Does Medical Excellence Capital lead rounds?
- Medical Excellence Capital typically participates in rounds rather than leading them.
- Who does Medical Excellence Capital co-invest with?
- Medical Excellence Capital most often shares deals with ARCH Venture Partners, Andreessen Horowitz, Global Brain, among 27 tracked co-investors.
From the blog
visit blog ↗Recent posts cover advancements in regenerative medicine including iPSC-derived cell therapies for neurodegenerative diseases and nonviral gene delivery platforms for genetic disorders. AI summary
Media · Podcasts & interviews
featuring the teamAsk an Investor featuring Kim Kamdar of Medical Excellence Capital
UC San Diego Innovation · Kim Kamdar
Co-investors · 16
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
Foothill Ventures is a technology-focused venture fund based in Los Altos, California, run by a team with founder and operator backgrounds. It makes early-stage investments in frontier technology, particularly infrastructure and AI applications.
Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that improve patients' lives.
Agent Capital is a healthcare venture capital firm that invests in novel, differentiated therapeutics and treatments addressing unmet patient needs across all stages of development.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
Illuminate Ventures is an early-stage venture firm focused on B2B/enterprise software companies, typically serving as a startup's first institutional investor and leading Series Seed rounds.
Johnson & Johnson Innovation is the innovation arm of Johnson & Johnson, working to advance life science innovation through early partnerships, incubation via JLABS, venture investing through JJDC, and late-stage partnerships to address global health challenges.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
Morgenthaler is a venture capital and private equity firm that has focused on building valuable companies for over 40 years.
▶4 more co-investors
Cofounders CapitalQuesta CapitalHealthQuest CapitalVertex Ventures HC
Firms observed investing alongside Medical Excellence Capital, from public investor directories. Shared companies are the overlap with Medical Excellence Capital's recorded portfolio.
Similar investors
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Rising Tide is a venture capital firm investing across sectors including healthcare, life sciences, AI infrastructure, space and communications, fintech, and crypto.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
Seido Capital is a North American venture capital firm investing in life sciences and deep tech companies from pre-seed to IPO, building on the legacy of the Belgian Theodorus funds.